특발성 폐섬유증의 통합의료 협진 모델 개발을 위한 의료진 및 환자 대상 설문조사 연구
Research for the Development of an Integrated Medical System for Idiopathic Pulmonary Fibrosis: Based on an Analysis of Questionnaire Survey in Doctor and Patient Groups
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: In this study, a questionnaire survey was conducted for doctors and patients to obtain basic data necessary for the development of an integrated medical system for idiopathic pulmonary fibrosis (IPF). Methods: Questionnaires were developed separately for doctors and patients through an expert group meeting. The survey subjects were recruited online and offline, and finally, responses from 231 doctors and 59 patients were used for statistical analysis. Results: The most important parts in the treatment of IPF for both doctors and patients were the “improvement of respiratory symptoms,” “improvement of quality of life,” and “prevention of disease progression.” Antifibrotic agents were prescribed at a high rate, and 100% of the specialists in Western medicine (WM) and 45.8% of patients reported experiencing side effects. As for the additional payment costs that patients considered as affordable for an integrated medical system, “under 50,000 won (about 38$)” was reported the most in both doctor and patient groups. With regard to the reasons for their reluctance to recommend an integrated medical system for IPF, specialists in WM responded highly to “uncertain evidence for treatment effectiveness.” Regarding complementary and alternative medicine therapies that can be beneficial in patients with IPF, “lifestyle management,” “diet management,” “herb,” “relaxation therapy,” and “psychotherapy” were ranked high in both doctor and patient groups. Conclusions: In this study, a questionnaire survey on IPF was conducted to review actual treatment status, analyze shortcomings, and identify considerations for the development of an integrated medical system for IPF in the future.
Abstract
Objective: In this study, a questionnaire survey was conducted for doctors and patients to obtain basic data necessary for the development of an integrated medical system for idiopathic pulmonary fibrosis (IPF). Methods: Questionnaires were developed separately for doctors and patients through an expert group meeting. The survey subjects were recruited online and offline, and finally, responses from 231 doctors and 59 patients were used for statistical analysis. Results: The most important parts in the treatment of IPF for both doctors and patients were the “improvement of respiratory symptoms,” “improvement of quality of life,” and “prevention of disease progression.” Antifibrotic agents were prescribed at a high rate, and 100% of the specialists in Western medicine (WM) and 45.8% of patients reported experiencing side effects. As for the additional payment costs that patients considered as affordable for an integrated medical system, “under 50,000 won (about 38$)” was reported the most in both doctor and patient groups. With regard to the reasons for their reluctance to recommend an integrated medical system for IPF, specialists in WM responded highly to “uncertain evidence for treatment effectiveness.” Regarding complementary and alternative medicine therapies that can be beneficial in patients with IPF, “lifestyle management,” “diet management,” “herb,” “relaxation therapy,” and “psychotherapy” were ranked high in both doctor and patient groups. Conclusions: In this study, a questionnaire survey on IPF was conducted to review actual treatment status, analyze shortcomings, and identify considerations for the development of an integrated medical system for IPF in the future.
참고문헌 (31)
- King Jr TE, "Idiopathic pulmonary fibrosis", The Lancet, 378(9807), pp.1949~1961 (2011)
- Richeldi L, "Idiopathic pulmonary fibrosis", The Lancet, 389(10082), pp.1941~1952 (2017)
- Raghu G, "Comorbidities in idiopathic pulmonary fibrosis patients : a systematic literature review", European Respiratory Journal, 46(4), pp.1113~1130 (2015)
- Khor YH, "Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy : a systematic review", European Respiratory Review, 29(157), pp.190158~ (2020)
- Kim SW, "Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea", Int J Tuberc Lung Dis, 21(2), pp.230~235 (2017)
- Zaman T, "Risk factors for the development of idiopathic pulmonary fibrosis : A review", Curr Pulmonol Rep, 7(4), pp.118~125 (2018)
- Cox IA, "Health-related quality of life of patients with idiopathic pulmonary fibrosis : a systematic review and meta-analysis", European Respiratory Review, 29(158), pp.200154~ (2020)
- Gao J, "Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis : a longitudinal analysis of the Swedish IPF Registry", Respiratory research, 22(1), pp.40~ (2021)
- Noble PW, "Pirfenidone for idiopathic pulmonary fibrosis : analysis of pooled data from three multinational phase 3 trials", European Respiratory Journal, 47(1), pp.243~253 (2016)
- Lancaster L, "Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib : pooled data from six clinical trials", BMJ Open Respiratory Research, 6(1), pp.e000397~ (2019)
- Kreuter M, "Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice : insights-IPF registry", Respiratory research, 18(1), pp.139~ (2017)
- Kim ES, "Pirfenidone : a review of its use in idiopathic pulmonary fibrosis", Drugs, 75(2), pp.219~230 (2015)
- Margaritopoulos GA, "Pirfenidone improves survival in IPF : results from a real-life study", BMC pulmonary medicine, 18(1), pp.177~ (2018)
- Cohen MH, "Complementary and integrative medical therapies, the FDA, and the NIH : definitions and regulation", Dermatologic therapy, 16(2), pp.77~84 (2003)
- Ji K, "Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis : a meta-analysis", Evidence-Based Complementary and Alternative Medicine, 2020, pp.1752387~ (2020)
- Kalnins P, "Prolonged Survival in a Patient with Idiopathic Pulmonary Fibrosis Receiving Acupuncture and DHEAPromoting Herbs with Conventional Management : A Case Report", The Permanente Journal, 23, pp.18~074 (2019)
- Li B, "Umbilical moxibustion for patients with idiopathic pulmonary fibrosis complicated with gastroesophageal reflux of lung-spleen qi deficiency", Chinese Acupuncture & Moxibustion, 39(3), pp.241~245 (2019)
- Yu X, "Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients : a systematic review and meta-analysis", BioMed research international, 2019, pp.8498603~ (2019)
- Guler SA, "Nondrug Treatments for Idiopathic Pulmonary Fibrosis : IPF Part 3", American journal of respiratory and critical care medicine, 203(4), pp.P10~P11 (2021)[DOI]
- Mercader-Barceló J, "Insights into the role of bioactive food ingredients and the microbiome in idiopathic pulmonary fibrosis", International Journal of Molecular Sciences, 21(17), pp.6051~ (2020)
- Duck A, "IPF Care : a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe", Advances in therapy, 32(2), pp.87~107 (2015)
- 이혜윤, "의⋅한의 협진 1단계 시범 사업 참여 의료인 대상 만족도 및 요구도 조사", 동의생리병리학회지, 32(2), pp.134~140 (2018), 한의병리학회[DOI]
- Li M, "Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis : An Overview of Systematic Review", Alternative Therapies in Health and Medicine, pp.AT8195~ (2023)
- Kim Y, "Nutritional factors affecting the mortality in patients with chronic lung disease", Current Developments in Nutrition, 4(Supplement_2), pp.41~ (2020)
- Volpato E, "Relaxation techniques for people with chronic obstructive pulmonary disease : a systematic review and a meta-analysis", Evidence-Based Complementary and Alternative Medicine, 2015, pp.628365~ (2015)
- 최원일, "특발성폐섬유증 치료의 현재와 미래", 대한의사협회지, 64(4), pp.256~263 (2021), 대한의사협회
- Shimizu Y, "Gastrointestinal symptoms in idiopathic pulmonary fibrosis patients treated with pirfenidone and herbal medicine", Journal of Biological Regulators and Homeostatic Agents, 28(3), pp.433~442 (2014)
- 박지은, "한방의료 이용현황 및 이용결정요인에 관한 연구 -고령화 패널을 이용하여-", 대한한의학회지, 32(1), pp.97~108 (2011), 대한한의학회
- Vainshelboim B, "Lifestyle Behaviors and Clinical Outcomes in Idiopathic Pulmonary Fibrosis", Respiration, 95(1), pp.27~34 (2018)
- Poswal FS, "Herbal teas and their health benefits : a scoping review", Plant Foods for Human Nutrition, 74(3), pp.266~276 (2019)
- Van Manen M, "What patients with pulmonary fibrosis and their partners really think; live patient and partner survey on pulmonary fibrosis in the netherlands and germany. A41. Here there and everywhere: ILD observational studies", 191, pp.A1591~ (2015), American Thoracic Society